DE602004009943D1 - 9,10-alpha,alpha-oh-taxananaloga und verfahren zu deren herstellung - Google Patents

9,10-alpha,alpha-oh-taxananaloga und verfahren zu deren herstellung

Info

Publication number
DE602004009943D1
DE602004009943D1 DE602004009943T DE602004009943T DE602004009943D1 DE 602004009943 D1 DE602004009943 D1 DE 602004009943D1 DE 602004009943 T DE602004009943 T DE 602004009943T DE 602004009943 T DE602004009943 T DE 602004009943T DE 602004009943 D1 DE602004009943 D1 DE 602004009943D1
Authority
DE
Germany
Prior art keywords
group
hydroxyl
alpha
present
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004009943T
Other languages
English (en)
Other versions
DE602004009943T2 (de
Inventor
James D Mcchesney
James Ferrara
Jan Zygmut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tapestry Pharmaceuticals Inc
Original Assignee
Tapestry Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tapestry Pharmaceuticals Inc filed Critical Tapestry Pharmaceuticals Inc
Publication of DE602004009943D1 publication Critical patent/DE602004009943D1/de
Application granted granted Critical
Publication of DE602004009943T2 publication Critical patent/DE602004009943T2/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE602004009943T 2003-09-25 2004-09-27 9,10-alpha,alpha-oh-taxananaloga und verfahren zu deren herstellung Expired - Fee Related DE602004009943T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50668003P 2003-09-25 2003-09-25
US506680P 2003-09-25
PCT/US2004/031816 WO2005030150A2 (en) 2003-09-25 2004-09-27 9,10-α,α-OH-TAXANE ANALOGS AND METHODS FOR PRODUCTION THEREOF

Publications (2)

Publication Number Publication Date
DE602004009943D1 true DE602004009943D1 (de) 2007-12-20
DE602004009943T2 DE602004009943T2 (de) 2008-08-28

Family

ID=34393186

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004009943T Expired - Fee Related DE602004009943T2 (de) 2003-09-25 2004-09-27 9,10-alpha,alpha-oh-taxananaloga und verfahren zu deren herstellung

Country Status (14)

Country Link
US (8) US7745650B2 (de)
EP (2) EP1785416A3 (de)
JP (5) JP4874102B2 (de)
CN (1) CN1886400A (de)
AT (1) ATE377593T1 (de)
AU (1) AU2004275881A1 (de)
CA (1) CA2539975C (de)
DE (1) DE602004009943T2 (de)
DK (1) DK1664033T3 (de)
ES (1) ES2295937T3 (de)
HR (1) HRP20080057T3 (de)
PL (1) PL1664033T3 (de)
PT (1) PT1664033E (de)
WO (1) WO2005030150A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE377593T1 (de) 2003-09-25 2007-11-15 Tapestry Pharmaceuticals Inc 9,10-alpha,alpha-oh-taxananaloga und verfahren zu deren herstellung
EP2634252B1 (de) 2005-02-11 2018-12-19 University of Southern California Verfahren zur Expression von Proteinen mit Disulfidbrücken
AU2006331674A1 (en) * 2005-12-21 2007-07-05 Tapestry Pharmaceuticals, Inc. Processes for taxane derivatives and intermediates useful therein
WO2007073383A1 (en) * 2005-12-21 2007-06-28 Tapestry Pharmaceuticals, Inc. Novel compounds and methods for forming taxanes and using the same
US20090306400A1 (en) * 2006-03-27 2009-12-10 Henri John T Convergent process for the synthesis of taxane derivatives.
WO2007130501A2 (en) * 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
US7847111B2 (en) 2006-06-19 2010-12-07 Canada Inc. Semi-synthetic route for the preparation of paclitaxel, docetaxel, and 10-deacetylbaccatin III from 9-dihydro-13-acetylbaccatin III
EP2029563A4 (de) * 2006-06-12 2009-12-02 Canada Inc 6570763 Halbsynthetische route zur herstellung von paclitaxel, docetaxel und 10-deacetylbaccatin iii aus 9-dihydro-13-acetylbaccatin iii
WO2008106621A1 (en) * 2007-02-28 2008-09-04 Tapestry Pharmaceuticals, Inc Taxane analogs for the treatment of brain cancer
US11786504B2 (en) 2006-09-28 2023-10-17 Tapestry Pharmaceuticals, Inc. Taxane analogs for the treatment of brain cancer
US11873308B2 (en) 2006-11-06 2024-01-16 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
WO2008121476A1 (en) 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
US20080207743A1 (en) * 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
US9227983B2 (en) 2011-04-07 2016-01-05 Arbor Therapeutics, LLC Taxane and abeo-taxane analogs
SG194128A1 (en) * 2011-04-07 2013-11-29 Arbor Therapeutics Llc Taxane and abeo-taxane analogs
SG195018A1 (en) * 2011-06-06 2013-12-30 Arbor Therapeutics Llc Acid-labile lipophilic prodrugs of cancer chemotherapeutic agents

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US6794523B2 (en) * 1991-09-23 2004-09-21 Florida State University Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them
US5352806A (en) * 1992-04-17 1994-10-04 Abbott Laboratories Taxol derivatives
FR2697019B1 (fr) 1992-10-15 1994-11-25 Rhone Poulenc Rorer Sa Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
DK0668762T3 (da) * 1992-11-13 2004-01-05 Univ Florida State Isobytenyl-substituerede taxaner og farmaceutiske præparater deraf
AU686137B2 (en) 1993-03-05 1998-02-05 Florida State University C9 taxane derivatives and pharmaceutical compositions containing them
US6710191B2 (en) * 1993-03-05 2004-03-23 Florida State University 9β-hydroxytetracyclic taxanes
EP0687260B1 (de) * 1993-03-05 2003-02-19 Florida State University Verfahren zur Herstellung von 9-Desoxotaxanen
EP1228759B1 (de) * 1993-03-22 2004-12-15 Florida State University Pharmazeutische Zusammenstellungen enthaltende eine furyl oder thienyl substituierte Seitenkette
FR2707293A1 (fr) 1993-07-08 1995-01-13 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2715846A1 (fr) * 1994-02-07 1995-08-11 Rhone Poulenc Rorer Sa Nouvelle composition pharmceutique à base de taxoïdes.
IT1275936B1 (it) 1995-03-17 1997-10-24 Indena Spa Derivati della 10-deacetilbaccatina iii e della 10-deacetil-14b- idrossibaccatina iii loro metodo di preparazione e formulazioni
US5635531A (en) * 1996-07-08 1997-06-03 Bristol-Myers Squibb Company 3'-aminocarbonyloxy paclitaxels
US5739359A (en) 1997-01-24 1998-04-14 Virginia Tech Intellectual Properties, Inc. Methods for preparing 1-deoxy paclitaxels
US6048990A (en) * 1998-05-01 2000-04-11 Napro Biotherapeutics, Inc. Method for selective acylation of C-2'-O-protected-10-hydroxy-taxol at the C-10 position
AU776767B2 (en) * 2000-02-02 2004-09-23 Florida State University Research Foundation, Inc. C10 heterosubstituted acetate taxanes as antitumor agents
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
US6825166B2 (en) 2001-03-23 2004-11-30 Tapestry Pharmaceuticals, Inc. Molecular conjugates for use in treatment of cancer
CA2354471A1 (en) 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C10 ester substituted taxanes
WO2003053350A2 (en) 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
US6898834B1 (en) * 2003-03-03 2005-05-31 Westbridge Pty Ltd Barrel stave reclaim
EP1894921A3 (de) 2003-09-25 2008-03-12 Tapestry Pharmaceuticals, Inc. 9, 10-Alpha, Alpha-OH-Taxan-Analoga und Herstellungsverfahren dafür
ATE377593T1 (de) 2003-09-25 2007-11-15 Tapestry Pharmaceuticals Inc 9,10-alpha,alpha-oh-taxananaloga und verfahren zu deren herstellung
EP1888121A2 (de) 2005-05-12 2008-02-20 Tapestry Pharmaceuticals, Inc. Gegen krebs gerichtete konjugate mit einem succinyl- oder glutaryl-linker
AU2006331674A1 (en) 2005-12-21 2007-07-05 Tapestry Pharmaceuticals, Inc. Processes for taxane derivatives and intermediates useful therein
WO2007073383A1 (en) 2005-12-21 2007-06-28 Tapestry Pharmaceuticals, Inc. Novel compounds and methods for forming taxanes and using the same
US20090306400A1 (en) 2006-03-27 2009-12-10 Henri John T Convergent process for the synthesis of taxane derivatives.
WO2008106621A1 (en) 2007-02-28 2008-09-04 Tapestry Pharmaceuticals, Inc Taxane analogs for the treatment of brain cancer
WO2008121476A1 (en) 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
US20080207743A1 (en) 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment

Also Published As

Publication number Publication date
WO2005030150A3 (en) 2005-07-14
CA2539975C (en) 2012-11-20
CN1886400A (zh) 2006-12-27
JP6216417B2 (ja) 2017-10-18
JP2007506792A (ja) 2007-03-22
EP1664033B1 (de) 2007-11-07
EP1785416A3 (de) 2007-05-30
US20180125811A1 (en) 2018-05-10
US9402824B2 (en) 2016-08-02
US20150133536A1 (en) 2015-05-14
US8962870B2 (en) 2015-02-24
US7745650B2 (en) 2010-06-29
US20120077871A1 (en) 2012-03-29
PL1664033T3 (pl) 2008-04-30
ATE377593T1 (de) 2007-11-15
EP1664033A2 (de) 2006-06-07
JP2011012070A (ja) 2011-01-20
JP2016180006A (ja) 2016-10-13
US9820962B2 (en) 2017-11-21
US20190142784A1 (en) 2019-05-16
JP2011137045A (ja) 2011-07-14
HRP20080057T3 (en) 2008-02-29
DK1664033T3 (da) 2008-03-25
US10238621B2 (en) 2019-03-26
US20200237708A1 (en) 2020-07-30
JP2014196345A (ja) 2014-10-16
JP5525394B2 (ja) 2014-06-18
AU2004275881A1 (en) 2005-04-07
DE602004009943T2 (de) 2008-08-28
EP1664033A4 (de) 2006-09-13
US20100324128A1 (en) 2010-12-23
WO2005030150A2 (en) 2005-04-07
JP6106634B2 (ja) 2017-04-05
JP5629632B2 (ja) 2014-11-26
CA2539975A1 (en) 2005-04-07
US20050148657A1 (en) 2005-07-07
JP4874102B2 (ja) 2012-02-15
US10639293B2 (en) 2020-05-05
EP1785416A2 (de) 2007-05-16
US20160331718A1 (en) 2016-11-17
ES2295937T3 (es) 2008-04-16
PT1664033E (pt) 2008-01-17
US7879904B2 (en) 2011-02-01

Similar Documents

Publication Publication Date Title
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
ATE536875T1 (de) Verfahren und zwischenzusammensetzungen zur herstellung von statinen, insbesondere rosuvastatin
ATE527270T1 (de) Herstellung von organosilanestern
ATE372343T1 (de) Verfahren zur herstellung von 6-alkoxy-(6h)- dibenz(c,e)(1,2)-oxaphosphorinen
ATE422200T1 (de) Verfahren zur herstellung substituierter nikotinsäureester
DE60327571D1 (de) Verfahren zur Herstellung von Polymerverbindungen durch Eliminierungsreaktion
WO2003031499A3 (de) Photochemisch und/oder thermisch strukturierbare harze auf silanbasis, einstufiges verfahren zu deren herstellung, dabei einsetzbare ausgangsverbindungen und herstellungsverfahren für diese
JP2011526896A5 (de)
ATE372332T1 (de) Verfahren zur herstellung von zwischenverbindungen in der herstellung von discodermolid und discodermolid-analoga
EP1810968A3 (de) 9, 10-a, a-OH-Taxan-Analoge und Herstellungsverfahren dafür
DE69616719D1 (de) Verfahren zur herstellung von taxol und seiner derivate
DE602005025497D1 (de) Verfahren zur herstellung von halogensubstituiertem benzoldimethanol
ATE473989T1 (de) Eine phosphorylcholingruppe enthaltende verbindung, und verfahren zu ihrer herstellung
DE60017151D1 (de) Verfahren zur reinigung fluorierter hydroxylverbindungen
EP1708026A4 (de) Lichtempfindliche polymerzusammensetzung, prozess zur erzeugung einer struktur und elektronisches teil
ATE444323T1 (de) Neuartige epoxidverbindungen und verfahren zu ihrer herstellung
ATE553081T1 (de) Verfahren zur herstellung einer bakteriziden pyridinverbindung, und bakterizide pyridinverbindung
DE602004020050D1 (de) Verfahren zur herstellung substituierter imidazolderivate und in dem verfahren verwendete zwischenprodukte
ATE387421T1 (de) Verfahren zur herstellung von michael-addukten
DE50107832D1 (de) Verfahren zur herstellung von chlorcarbonsäurechloriden
BRPI0412505A (pt) processo para preparar organohidrogensiloxanos cìclicos
DE01924282T1 (de) Verfahren zur herstellung von taxanderivaten
HK1114084A1 (en) Method for producing thiocarbamate derivative
ATE296321T1 (de) Verfahren zur herstellung von teilgeschützten poly(hydroxystryolen)
ATE555089T1 (de) Verfahren zur herstellung von -ketoacetalen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee